Related Experiment Video
Updated: May 7, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Reclassification of European patients' cardiovascular risk using the updated Systematic Coronary Risk Evaluation
Julian P Halcox1, Florence Tubach2, Ogün Sazova3
1Wales Heart Research Institute, Cardiff University School of Medicine, UK halcoxjp@cardiff.ac.uk.
Abstract:
Data from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; ClinicalTrials.gov; NCT00882336) was used to assess the proportions of patients aged 50-65 years free of diabetes and not receiving lipid-lowering therapy (LLT) considered to be at low (<1%), intermediate (1% to <5%) and high (≥5%) 10-year risk of cardiovascular mortality according to the Systematic Coronary Risk Evaluation (SCORE) algorithm and the updated algorithm that considers patients' total cholesterol and high-density lipoprotein cholesterol (HDL-C) levels as independent variables (SCORE-HDL). Of 2321 patients analysed, 19.3%, 60.7% and 20.0% were considered to be at low, intermediate and high cardiovascular risk respectively according to SCORE, and 25.7%, 57.2% and 17.1% respectively according to SCORE-HDL. Thus, there was an overall trend towards reclassification from higher to lower risk categories when SCORE-HDL was compared with SCORE.
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Heart Failure IV: Classification and Diagnostic Evaluation
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management